舒尼替尼治疗转移性肾细胞癌9例报告

目的评价舒尼替尼治疗转移性肾细胞癌的疗效和安全性。方法转移性肾细胞癌患者9例,均为男性。年龄27～79岁（中位年龄56岁）。接受根治性肾切除术者7例,原发灶无法切除者2例。6例曾接受免疫治疗。透明细胞癌8例,乳头状癌1例。转移灶部位：肺转移3例,肝转移4例,淋巴结转移4例,肾上腺转移1例,骨转移1例,脑转移1例,其中4例患者为多发转移。每例患者至少有1处可测量病灶,即目标病灶。治疗时间3～15个月。治疗方案：舒尼替尼50 mg/d,连续服用4周后停药2周,6周为一个周期,直至肿瘤进展或出现不可耐受的不良反应。结果9例均可评价疗效。其中完全缓解1例,部分缓解3例,疾病稳定5例。总缓解率为44.4%（4/9）,疾病控制率为100%（9/9）。中位无进展生存时间42周（16～62周）。常见不良反应有腹泻、乏力、手足综合征、白细胞减少、高血压。结论舒尼替尼治疗转移性肾细胞癌疗效显著,不良反应多为轻中度1～2级。

Reports of sunitinib in the treatment of nine patients with metastatic renal cell carcinoma

Objective To evalute the efficacy and safety of sunitinib in the treatment of metastatic renal cell carcinoma（mRCC）. Methods Seven patients with mRCC after radical nephrectomy and two patient with locally advanced renal cell carcinoma and unresectable primary renal tumor were eligible for this study.The pathological diagnosis of primary tumors were clear cell carcinona in 8 patients,papillary carcinoma in 1 patient.The metastatic sites of all the patients included 3 in lung,4 in liver,4 in retroperitoneal nodes,1 in adrenal gland,1 in bone and 1 in brain.The regimen was oral intake of sunitinib（50 mg daily for 4 weeks,followed by 2 weeks off treatment,4/2 schedule） until the disease progression or toxicity becoming intolerable. Results PD has not been observed in our group.1 patient achieved CR,3 patients achieved PR,in which 1 have its metastatic site in liver obvious shrinkage.5 patients achieved SD,in which 2 have stable disease for more than 12 months. Conclusions Sunitinib was effective in both controlling tumor growth and relieving the symptoms associated with disease progression,and its toxicity was mild.